Last updated: February 3, 2026
Executive Summary
OPTIRAY 240, an iodine-based contrast agent primarily used in diagnostic imaging, presents notable investment opportunities amid increasing demand for advanced medical imaging. The compound's market expansion hinges on technological advancements, regulatory approvals, and regional healthcare infrastructure development. Current market value estimates for OPTIRAY 240 range from USD 200 million to USD 350 million, with projected compounded annual growth rates (CAGR) of 4-6% over the next five years. This report assesses the investment landscape, key market drivers, competitive positioning, financial forecasts, and strategic considerations critical for stakeholders.
What Is OPTIRAY 240?
OPTIRAY 240 (trade name, generic: iodine contrast media) is a water-soluble, iodinated contrast agent used predominantly in computed tomography (CT) scans and angiography procedures. Its high iodine concentration (240 mgI/mL) facilitates enhanced imaging contrast, enabling detailed vascular and tissue visualization.
Product Features and Specifications
| Attribute |
Details |
| Active Ingredient |
Iopamidol |
| Iodine Concentration |
240 mg/mL |
| Form |
Injectable solution |
| Approved Uses |
CT, angiography, venography, urography |
| Delivery System |
Vials, pre-filled syringes |
Comparison with Competitors
| Product |
Iodine Concentration |
Market Presence |
Regulatory Status |
Key Differentiator |
| OPTIRAY 240 |
240 mg/mL |
Global |
Approved in multiple regions |
High iodine concentration, low osmolality |
| Iohexol |
240-350 mg/mL |
Widely used |
Approved worldwide |
Higher iodine concentration, varied formulations |
| Iomeron |
350 mg/mL |
European dominant |
Extensive approvals |
Higher iodine dose options |
Market Dynamics for OPTIRAY 240
Global Market Size and Forecast
| Year |
Estimated Market Value (USD million) |
CAGR (2023-2028) |
Notes |
| 2023 |
200 – 350 |
4-6% |
Driven by expanding diagnostic imaging needs |
| 2028 |
245 – 370 |
|
|
The global medical imaging contrast media market was valued at approximately USD 7.4 billion in 2022, with iodinated agents constituting roughly 45% of the total. OPTIRAY 240, as a high-end iodinated contrast agent, holds a segment of this market, especially favored in high-resolution imaging contexts.
Regional Breakdown
| Region |
Market Share (2023) |
Key Drivers |
Challenges |
| North America |
35-40% |
Advanced healthcare infrastructure, high imaging demand |
Regulatory hurdles, drug pricing policies |
| Europe |
25-30% |
Well-established radiology services |
Pricing pressures, GDPR compliance |
| Asia-Pacific |
20-25% |
Growing healthcare penetration, aging population |
Regulatory approval delays |
| Latin America |
5-10% |
Increasing investment in healthcare |
Limited access to advanced imaging |
Major Market Drivers
- Rising incidence of chronic and cardiovascular diseases: Drives demand for detailed vascular imaging.
- Technological advancements: Innovations like dual-energy CT and 3D imaging increase contrast media necessity.
- Healthcare infrastructure expansions: Especially in Asia-Pacific and emerging markets.
- Regulatory approvals: Streamline access to new markets and formulations.
- User preferences: Shift toward low-osmolality, high-iodine-concentration agents for improved safety profiles.
Key Market Challenges
- Safety and toxicity concerns: Potential for allergic reactions and nephrotoxicity.
- Regulatory complexities: Varying approval processes across jurisdictions.
- Competition: Market saturation with alternative contrast agents.
- Pricing pressures: Cost containment in healthcare systems.
Financial Trajectory and Investment Outlook
Revenue Streams
| Source |
Description |
Contribution Estimate (2023) |
| Direct Sales (Pharmacies, Hospitals) |
Primary sales channel, bulk procurement by healthcare providers |
80-85% |
| Licensing & Partnership Revenues |
Collaborative agreements with regional distributors or manufacturers |
10-15% |
| R&D Funding and Grants |
Development of next-gen formulations or delivery systems |
5-10% |
Revenue Projections (USD Million)
| Year |
Low Estimate |
High Estimate |
CAGR (2023-2028) |
Assumptions |
| 2023 |
200 |
350 |
— |
Current market size |
| 2024 |
208 – 365 |
368 – 385 |
4-6% |
Moderate market growth |
| 2025 |
217 – 382 |
385 – 405 |
|
Increased adoption, expanded indications |
| 2026 |
226 – 400 |
404 – 426 |
|
Regulatory approvals, regional market penetration |
| 2027 |
236 – 420 |
423 – 448 |
|
New formulations in development |
| 2028 |
245 – 370 |
445 – 470 |
|
Market maturation, pricing pressures |
Cost Structure and Profitability
| Cost Element |
Approximate Percentage of Revenue |
Notes |
| Raw materials (Iodine, excipients) |
10-15% |
Volatility impacts margins |
| Manufacturing and Quality Control |
12-20% |
Regulatory compliance costs |
| Distribution and Logistics |
5-8% |
Regional transportation efficiency |
| R&D and Product Development |
8-12% |
Pipeline development |
| Sales, Marketing, and Regulatory |
10-15% |
Promotional activities |
Profit Margins: Operating margins are estimated at 25-30%, with potential for scale efficiencies as manufacturing footprints expand.
Competitor Analysis and Market Positioning
| Competitor |
Market Share (Estimated) |
Pricing Strategy |
Key Differentiators |
Regulatory Status |
| Bracco Imaging |
20-25% |
Premium |
Extensive portfolio, strong regional footprint |
Approved in US, EU, ROW |
| GE Healthcare |
15-20% |
Varies |
Integrated imaging solutions, broad product lines |
Global approvals |
| Guerbet |
10-15% |
Competitive |
Innovation in low-osmolality agents |
Approved worldwide |
| Others (e.g., Bayer) |
5-10% |
Price-sensitive |
Competitive pricing, niche formulations |
Varies |
Strategic Positioning for OPTIRAY 240
- Focus on high-end imaging centers prioritizing image quality and safety.
- Leverage regional regulatory approvals to expand market penetration.
- Innovate in formulation and delivery mechanisms for improved safety profiles.
Regulatory and Policy Landscape
| Region |
Regulatory Authority |
Approval Process (months) |
Key Requirements |
| US |
FDA (Food & Drug Administration) |
12-24 |
Safety data, clinical trial results |
| European Union |
EMA (European Medicines Agency) |
10-18 |
Risk management plans, pharmacovigilance |
| China |
NMPA (National Medical Products Administration) |
12-24 |
Local clinical data, manufacturing standards |
| Japan |
PMDA (Pharmaceuticals and Medical Devices Agency) |
9-15 |
Registration dossier, toxicity profiles |
Implication: Streamlined approval processes in developed markets support timely commercialization but necessitate rigorous data.
Strategic Considerations for Investors
| Consideration |
Implication |
| Market growth potential |
Favorable, driven by rising imaging demand |
| Competitive landscape |
Moderate fragmentation, opportunities to consolidate or differentiate |
| Regulatory environment |
Complex but manageable with proper compliance |
| Product innovation opportunities |
High, with potential for safer, more effective formulations |
| Pricing and reimbursement policies |
Variable; impacts profit margins |
Key Risks
| Risk Category |
Mitigation Strategies |
| Regulatory delays |
Robust early-stage clinical data, regional approval planning |
| Market saturation |
Differentiation through safety, efficacy, and regional partnerships |
| Raw material price fluctuations |
Long-term supply agreements |
| Competitive threats |
Continuous innovation, strategic collaborations |
Key Takeaways
- Market Growth: The global iodinated contrast media market, including OPTIRAY 240, is expected to grow at a CAGR of 4-6% through 2028, fueled by technological advances and healthcare infrastructure expansion.
- Financial Trajectory: Revenue estimates for OPTIRAY 240 suggest growth from USD 200–350 million in 2023 to potentially USD 245–470 million by 2028, assuming steady adoption and regulatory clearance.
- Competitive Positioning: OPTIRAY 240 can leverage its high iodine concentration and safety profile to distinguish itself in a competitive landscape dominated by Bracco, GE Healthcare, and Guerbet.
- Regulatory Dynamics: Approval timelines vary by region, with fast-track prospects in North America and Europe, but regulatory complexity remains a key hurdle.
- Investment Opportunities: Scalability, innovation potential, and emerging markets present favorable avenues, while risks include regulatory delays and competitive pressures.
Frequently Asked Questions
1. What factors influence the market penetration of OPTIRAY 240?
Market penetration depends on regulatory approvals, clinical efficacy, safety profile, regional healthcare infrastructure, and pricing strategies. Technological innovations and physician preference also significantly impact adoption.
2. How does OPTIRAY 240 compare to competing contrast agents in safety?
OPTIRAY 240 is formulated to have low-osmolality properties, reducing adverse reactions compared to older agents. However, allergic reactions and nephrotoxicity remain concerns, necessitating careful patient selection.
3. What are the key regulatory hurdles for OPTIRAY 240 in emerging markets?
Emerging markets often require local clinical trials, compliance with regional standards, and navigating complex approval processes, which can extend timelines and increase costs.
4. How might technological advancements affect the financial outlook of OPTIRAY 240?
Advances like dual-energy CT and improved delivery systems could enhance the utility and safety of contrast agents, expanding the market and potential revenue streams for OPTIRAY 240.
5. What strategic partnerships are crucial for expanding the market for OPTIRAY 240?
Partnerships with regional distributors, OEMs, and healthcare providers facilitate market access, while collaborations with regulatory agencies can streamline approval processes.
References
[1] MarketsandMarkets. "Contrast Media Market by Product Type, Application, and Region." 2022.
[2] Persistence Market Research. "Global Iodinated Contrast Media Market Outlook." 2022.
[3] US FDA. "Guidance for Industry and FDA Staff." 2021.
[4] European Medicines Agency. "Regulatory Guidelines for Diagnostic Products." 2022.
[5] Industry reports from IQVIA and GlobalData，2023.
